Arsenal Capital Partners has agreed to sell its portfolio company, Certara to EQT VII Fund for an enterprise value of $850 million. As part of the transaction, Arsenal Capital Partners will retain a minority ownership stake in Certara. The company’s current management team, led by Edmundo Muniz, MD, PhD, will continue to lead the organization, building on a multi-year track record of both organic growth and strategic acquisitions.
Certara is a provider of model-informed drug development technology and services, as well as a provider of regulatory science, writing, and submission management software and services. Certara’s solutions help inform the drug development and regulatory approval process and address the key efficacy, safety, productivity and commercial challenges facing the biopharma industry. The company serves 1,200 commercial companies, 250 academic institutions and numerous regulatory agencies, across 60 countries. Certara is headquartered in Princeton, New Jersey with over 500 employees globally, including key operations and senior management in Northern Europe.
“Arsenal’s healthcare team is committed to facilitating systemic improvement in the efficacy and safety of pharmaceutical and biotechnology treatments and cures,” Stephen McLean, Partner at Arsenal and Co-Head of the Healthcare practice, said. “We are proud of the significant contribution Certara is making to this critical initiative and the global leadership it has established. We are confident that our new partnership with EQT will enable Certara to further expand its industry leading capabilities.”
Jefferies LLC is serving as lead financial advisor and William Blair & Company as co-advisor to Certara. DLA Piper and Morgan, Lewis & Bockius LLP are serving as legal advisors to Certara. Centerview Partners is serving as financial advisor and Simpson Thacher & Bartlett LLP is serving as legal advisor to EQT VII.